Catalent, Inc. (NYSE:CTLT) Director Michelle R. Ryan Sells 2,800 Shares

by · The Cerbat Gem

Catalent, Inc. (NYSE:CTLT – Get Free Report) Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catalent Stock Up 0.2 %

CTLT stock traded up $0.14 during trading hours on Thursday, hitting $59.29. The company’s stock had a trading volume of 518,676 shares, compared to its average volume of 2,034,556. The company has a market capitalization of $10.76 billion, a PE ratio of -26.17, a price-to-earnings-growth ratio of 2.36 and a beta of 1.16. Catalent, Inc. has a 12 month low of $36.00 and a 12 month high of $61.20. The stock has a 50 day moving average price of $59.89 and a two-hundred day moving average price of $58.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) earnings per share. The business’s quarterly revenue was up 4.2% on a year-over-year basis. On average, equities research analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.

Institutional Trading of Catalent

Several institutional investors have recently modified their holdings of CTLT. Nisa Investment Advisors LLC lifted its holdings in shares of Catalent by 1.7% during the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after acquiring an additional 185 shares during the period. GAMMA Investing LLC grew its holdings in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Catalent by 1.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after buying an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in Catalent by 2.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after acquiring an additional 229 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after acquiring an additional 278 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have commented on CTLT. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Thursday. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Nine analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $59.83.

Read Our Latest Analysis on Catalent

About Catalent

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

See Also